4 Stocks With High Coverage Ratios Offer Safer Bets Going Into 2026

Zacks highlights four stocks—Life Time Group (LTH), Cardinal Health (CAH), LeMaitre Vascular (LMAT) and Flowserve (FLS)—that combine strong interest coverage ratios with Zacks Rank #2 and VGM Scores of A/B as potentially safer plays into 2026 amid rate and inflation uncertainty. Zacks Consensus for the current financial year implies LTH sales +13.8% and EPS +57.9% (trailing four-quarter surprise 22.4%, shares +16.5% Y/Y); CAH sales +16.2% and EPS +19.7% (surprise 9.4%, shares +73.3% Y/Y); LMAT sales +12.9% and EPS +30.1% (surprise 2.5%, shares -21.3% Y/Y); FLS sales +4.6% and EPS +31.9% (surprise 10.5%, shares +17.2% Y/Y). The screening also enforces liquidity and growth filters (price ≥ $5, 20-day avg volume >100k, historical and projected EPS growth above industry medians) to prioritize debt-servicing capacity and earnings resilience.

Analysis

Market structure: In a rising-rate, risk-off regime into 2026, firms with above‑median interest coverage (CAH, LTH, FLS, LMAT) gain relative share as customers and counterparties favor counterparties that can service debt — expect investors to rotate into high‑coverage healthcare and critical-infrastructure names; energy/capex suppliers (FLS) will benefit if commodity-driven capex resumes. Pricing power shifts to incumbents with stable cashflows (CAH distribution network, LTH membership model) while highly leveraged, cyclical peers face margin compression and higher cost of capital.

Risk assessment: Tail risks include an abrupt recession that compresses volumes (membership churn at LTH, elective-procedures slowdown for LMAT), regulatory action in drug distribution (CAH) or a sharp decline in industrial capex that chokes FLS revenues; probability moderate, impact high. Immediate window (days–weeks) is earnings/ratings sensitivity; 3–12 months is Fed policy and infrastructure spend realization; 1–3 years will test balance-sheet durability and potential M&A activity.

Trade implications: Favor quality long exposure to CAH and selective exposure to FLS for cyclical recovery, size positions modestly (1–3% NAV each), and use options to cap downside. Pair opportunities: long CAH (defensive distributor) vs reduced exposure or short of smaller, leveraged industrials; execute staggered entries over 4–8 weeks to manage earnings risk and scale into positions on <5% pullbacks.

Contrarian angles: Market consensus has likely over‑reward CAH already (stock +73% YTD) — downside from multiple expansion is possible; conversely LMAT’s −21% YTD may underprice its 30% projected EPS growth if elective procedure volumes normalize. Watch Fed hikes ±25bp, H1 2026 infrastructure funding windows, and next two earnings releases as catalysts that could reverse current positioning.

Key Decisions for Investors

• Establish a 2–3% NAV long position in Cardinal Health (CAH) within 2–6 weeks: buy shares or buy 12–18 month LEAPs ~5–10% OTM if you prefer leverage; set a hard stop-loss at −12% and a take-profit re‑evaluate at +25–30% or on a >200bp tightening in credit spreads.
• Build a 1.5–2% NAV constructive position in Flowserve (FLS) as a tactical recovery play tied to energy/infrastructure: enter via a 6–12 month bullish call spread (sell higher strike to fund) sized to limit capital at risk to 1–1.5% NAV; unwind if industrial revenue guidance falls >10% QoQ.
• Add a 1–1.5% NAV speculative buy on LeMaitre Vascular (LMAT) on any further weakness to a 10–15% drawdown from current levels, but hedge with 3‑month put protection ~7–10% OTM; target 35–45% upside if EPS revisions turn positive over next 2 quarters.
• Reduce cyclical small-cap industrial exposure by 3–5% NAV and rotate into high-coverage names (CAH/LTH/FLS); monitor the next Fed decision (within 30 days) and US infrastructure headlines — if rates rise >25bp unexpectedly, trim cyclicals an additional 2% and raise cash to 5–8% NAV.